R-CHOP versus R-FC Followed by Rituximab versus IFN Maintenance in Elderly Patients with MCL


R-CHOP versus R-FC Followed by Rituximab versus IFN Maintenance in Elderly Patients with MCL
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Stephanie A Gregory, MD (1/11/12)

Kluin-Nelemans JC et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: Outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Proc ASH 2011;Abstract 439.

Dr Gregory is the Elodia Kehm Chair of Hematology, Professor of Medicine and Director of the Hematology Section at Rush University Medical Center in Chicago, Illinois.